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The  liver  is a vital  organ  that  plays  a  major  role  in many  bodily  functions  from  protein  production  and
blood  clotting  to cholesterol,  glucose  and  iron  metabolism  and nutrition  storage.  Maintenance  of  liver
homeostasis  is  critical  for these  essential  bodily  functions  and  disruption  of  liver homeostasis  causes
various  kinds  of liver  diseases,  some  of which  have  high  mortality  rate.  Recent  research  advances  of
the  Hippo  signalling  pathway  have  revealed  its nuclear  effector,  Yes-associated  protein,  as  an  important
regulator  of  liver  development,  repair,  cell fate determination  and  tumorigenesis.  Therefore,  a preciseiver
AP
control  of  Yes-associated  protein  activity  is  critical  for the  maintenance  of liver  homeostasis.  This  review
is  going  to summarize  the  discoveries  on how  the  manipulation  of  Yes-associated  protein  activity  affects
liver  homeostasis  and induces  liver  diseases  and  the  regulatory  mechanisms  that  determine  the  Yes-
associated  protein  activity  in the  liver.  Finally,  we  will discuss  the potential  of  targeting  Yes-associated
protein  as  therapeutic  strategies  in liver diseases.
Published  by  Elsevier  Ltd  on behalf  of  Editrice  Gastroenterologica  Italiana  S.r.l.. Introduction
YAP (Yes-associated protein) was discovered 20 years ago in
n effort to identify interacting proteins to Src family kinase
es [1]. It burgeoned into a hot research objective after its
rosophila ortholog, Yki, was revealed as the effector of Hippo
ignalling pathway in 2005 [2]. The Hippo signalling pathway was
ecently discovered as a mechanism that controls organ size in
rosophila [2–4]. For a detailed review about the discovery of the
ippo signalling pathway in Drosophila,  see reviews from Duojia
an [5,6]. This review will focus on the Hippo signalling path-
ay in mammals. Components of the Hippo signalling pathway
re highly conserved throughout evolution. Accordingly, loss-of-
unction mutants ﬂies can be rescued with their corresponding
uman orthologs [3,4,7]. The core Hippo signalling pathway is kinase cascade (Fig. 1). The apical membrane-associated FERM
omain protein NF2 (neuroﬁbromin 2), directly binds and recruits
he Nuclear Dbf2-related family kinase, LATS1/2 (large tumour
∗ Corresponding author at: Olin E. Teague Medical Center, 1901 South 1st
treet, Bldg. 205, 1R58, Temple, TX 76504, United States. Tel.: +1 254 743 2502;
ax:  +1 254 743 0378.
E-mail address: hbai@sw.org (H. Bai).
ttp://dx.doi.org/10.1016/j.dld.2015.05.011
590-8658/Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.suppressor homolog 1/2), to the plasma membrane. Membrane
recruitment, in turn, promotes LATS1/2 phosphorylation by the
Ste-20 family protein kinase, MST1/2 (Mammalian STE20-Like Pro-
tein Kinase 1/2), together with the adaptor protein SAV1 (salvador
homolog 1) [8]. In turn, LATS1/2, in a complex with small regulator
protein MOB1 (Mps One Binder Homolog A), phosphorylates YAP.
Phosphorylated YAP is sequestered in cytoplasm via interaction
to 14-3-3 [9]. Cytoplasmic retention of YAP renders its interac-
tion with TEA domain family transcription factors TEADs (TEA
domain family members) [10] to another transcription cofactor,
Vgl4 (Vestigial like protein 4), thus stops YAP’s transcriptional out-
puts [9,11,12].
Increasing Yki activity by overexpressing Yki as well as by
ablating Yki’s upstream negative regulators, leads to a similar over-
growth phenotype in Drosophila due to increased proliferation and
inhibited apoptosis. These observations raised an exciting ques-
tion whether the Hippo pathway might play an analogous role
in mammals. To answer this question, mouse liver was chosen
as the model organ, since liver size is known to be tightly regu-
lated, constituting about 5% of the body weight [13]. Liver is a vital
organ that plays a major role in metabolism and has a number of
functions in the body, including glycogen storage, decomposition
of red blood cells, plasma protein synthesis, hormone production,
and detoxiﬁcation. It contains two kinds of epithelia, hepatocyte
l.
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Fig. 1. The Hippo signalling pathway in mammals. The Hippo signalling pathway negatively regulates Yes-associated protein activity. When the Hippo signalling is inactive,
Yes-associated protein accumulates in the nucleus and functions as transcriptional co-activator of the TEA domain family transcription factors. When the Hippo signalling
is  active, the apical membrane-associated neuroﬁbromin 2, directly binds and recruits the Nuclear Dbf2-related family kinase, large tumour suppressor homolog 1/2, to
the  plasma membrane. Membrane recruitment, in turn, promotes large tumour suppressor homolog 1/2 phosphorylation by mammalian STE20-Like Protein Kinase 1/2,
together  with the adaptor protein salvador homolog 1. In turn, large tumour suppressor homolog 1/2, in a complex with small regulator protein Mps One Binder Homolog A,
phosphorylates Yes-associated protein. Phosphorylated Yes-associated protein is sequestered in the cytoplasm via interaction to 14-3-3 proteins. Cytoplasmic retention of
Yes-associated protein renders its interaction with transcription partner TEA domain family transcription factors to another transcription cofactor, Vestigial like 4, thus stops
Y , neur
S omo
a
c
m
a
t
l
o
c
s
s
w
q
s
m
2
2
l
a
u
Y
c
s
i
s
a
a
t
g
s
[21–24]. Notch signalling deﬁciency results in a same biliary phe-es-associated protein’s transcriptional outputs. YAP, Yes-associated protein; NF2
TE20-Like Protein Kinase 1/2; SAV1, salvador homolog 1; MOB1, Mps One Binder H
nd cholangiocyte, both differentiated from hepatoblast. Hepato-
ytes make up 70–85% of the liver’s cytoplasmic mass and carry out
ost functions of the liver. A speciﬁc feature of hepatocyte is that
s a terminally differentiated cell, it retains ability to proliferate
o replenish damaged liver. In normal conditions, hepatocytes are
argely quiescent dividing approximately once per year. Transgenic
verexpression of YAP in hepatocyte immediately induces quies-
ent hepatocytes into cell cycle and dramatically expands the liver
ize to as much as 5 folds of the regular mouse liver weight [9]. This
tudy provided the ﬁrst direct evidence implicating the Hippo path-
ay in mammalian organ size control. And it evoked an interesting
uestion – whether YAP is normally required for liver homeosta-
is, which might be answered using liver-speciﬁc Yap knockout
ice.
. Physiological role of YAP in the liver
.1. Role of YAP in liver development
Complete knockout of Yap results in early embryonic letha-
ity [14]. To analyze YAP’s function at later stages of development
nd in adult tissue, conditional Yap knockout mice were generated
sing loxP technique (Yapf/f) [15]. By crossing with Alb-Cre mice,
ap deletion (Alb-Cre; Yapf/f) in both cholangiocytes and hepato-
ytes starts from E13.5 and achieves efﬁcient deletion at perinatal
tage (E18 and P1) [16,17], which is a critical time point during
ntrahepatic bile duct development [18,19]. Intrahepatic bile ducts
tart developing as early as around E13.5, hepatic progenitor cells
djacent to the portal veins undergo ductal commitment, forming
 structure known as the ductal plate. Around birth (E18 to P1),
ubulogenesis occurs at discrete points along the ductal plates,
iving rise to primitive ductal structures. These primitive ductal
tructures will incorporate into portal mesenchyme to becomeoﬁbromin 2; LATS1/2, large tumour suppressor homolog 1/2; MST1, Mammalian
log A; TEAD, TEA domain family transcription factors; Vgl4, Vestigial like 4.
mature bile ducts during the ﬁrst 2 weeks of life while the
remaining unincorporated ductal plates regress [18,19]. The duc-
tal plates form normally but the tubulogenesis fails in Alb-Cre;
Yapf/f liver, which results in bile duct paucity 2 weeks after
birth [15]. However, whether YAP affects ductal commitment
is not clear as Yap deletion in Alb-Cre; Yapf/f liver is not efﬁ-
cient until E18. Bile duct paucity in Alb-Cre; Yapf/f mice induces
compensatory ductular reaction, accompanied by steatosis and
ﬁbrosis in the adult liver. The hepatocytes develop normally
in these mice but with a higher turnover rate in the adult
liver. This high hepatocyte turnover may  be due to reduced
hepatocyte survival ability and bile duct paucity combined
together.
The important role of YAP in bile duct development was further
supported by the phenotype of liver speciﬁc Nf2 knockout mice
(Alb-Cre; Nf2f/f) [15]. NF2 is one of the upstream tumour suppressors
of the Hippo signalling pathway and negatively regulates Yki in
Drosophila [20]. Consistently, liver speciﬁc Nf2 deﬁciency results in
a reverse phenotype to Yap deﬁciency on bile duct development.
As a portion of cholangiocytes on the ductal plates form primitive
ducts in WT livers, and no cholangiocyte on the ductal plates forms
primitive ducts in Alb-Cre; Yapf/f livers, in Alb-Cre; Nf2f/f livers all the
cholangiocytes on the ductal plates become bile ducts [15]. This
bile ducts over-tubulogenesis phenotype of Alb-Cre; Nf2f/f liver is
due to increased YAP activity and can be suppressed by partial Yap
deletion [15].
The underlying mechanism of YAP-regulated bile duct tubulo-
genesis remains to be identiﬁed. Several studies have suggested
that the Notch signalling is one of the downstream effectors of YAPnotype as Yap deﬁciency [16,25]. However, direct genetic studies
are necessary to put Notch signalling downstream of YAP in bile
duct development.
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.2. Role of YAP in repairing damaged liver
Although YAP is critical for developing liver, it is largely dis-
ensable in quiescent adult liver. Yap deletion in adult mouse liver
y injecting Poly dI-dC to 8 weeks old Mx1-Cre; Yapf/f mice did not
ffect liver histology [26]. Similarly, Nf2 deletion in adult mouse
iver with adenovirus delivered Cre recombinase (Ade-Cre) or Mx1-
re only leads to very mild periporal hyperplasia compared to
ramatic and widespread biliary hyperplasia in Alb-Cre mediated
f2 deletion [27]. However, YAP is required to ensure sufﬁcient
egenerative proliferation in response to liver injury. Cholestatic
njury induced by ligation of the mouse common bile duct (BDL)
riggers repair responses including cholangiocyte and hepatocyte
roliferation, both of which peak at day 5 post-BDL and calm down
fter 14 days post-BDL [28]. YAP protein levels ﬁrst increase then
eturn to baseline correspondingly with cholangiocyte and hepa-
ocyte proliferation levels in isolated cholangiocytes, hepatocytes
nd whole liver [26]. Yap deletion with Mx1-Cre; Yapf/f signiﬁcantly
ecreases cholangiocyte proliferation, delays hepatocyte prolifer-
tion and enhances parenchymal damage after BDL [26]. It has also
een shown that YAP protein levels increase during the regener-
tion response in both mouse and rat partial hepatectomy model
29–31]. However, the role of YAP in the repair process after partial
epatectomy remains to be evaluated.
.3. Role of YAP in determining liver cell fate
Hepatocytes and cholangiocytes, both differentiated from hepa-
oblasts and/or putative liver progenitors, are the only two epithelia
n the liver. The relationship among hepatocytes, cholangiocytes
nd putative liver progenitors, as well as the factors that determine
heir cell fate speciﬁcation are long standing questions in the liver
esearch ﬁeld [32,33]. Recently, Yimlamai et al. provided deﬁnitive
vidence showing different YAP levels/activity could determine
epatic cell fates and mature hepatocytes retain the capacity of
edifferentiation [24]. In adult mouse liver, YAP is expressed at
igh levels in bile ducts, with many cholangiocytes displaying
obust nuclear YAP expression. Conversely, YAP is expressed at
ow levels in hepatocytes, where the distribution is throughout
he cell [15]. Further addition of active YAP protein in cholangio-
ytes leads to hyperplasia, but not to a ductal/progenitor-cell-like
ppearance. The interesting observation came from overexpressing
ctive form of YAP in mature hepatocytes, which dedifferentiates
he mature hepatocytes into ductal/progenitor cells. More impor-
antly, this hepatocyte-dedifferentiated ductal/progenitor cell can
edifferentiate into hepatocyte after YAP activity levels drop [24]. In
greement, Fitamant et al. also found that increasing endogenous
AP activity due to Mst1/2 deﬁciency results in conversion of hepa-
ocytes in periportal area to atypical ductal cells and override the
onation programme in pericentral hepatocytes [34]. Their studies
voked another interesting question: whether reducing YAP lev-
ls in cholangiocytes will transdifferentiate them into hepatocytes,
emains to be answered.
YAP also plays important role in other gastrointestinal tissues.
or example, YAP levels are critical for intestinal regeneration, pro-
enitor cells maintenance and differentiation [35,36]. Increasing
AP levels in pancreas affects pancreatic architecture [37,38]. A
etailed review about the Hippo signalling in other gastrointestinal
issues can be found in reviews of Yu et al. [39]
. YAP activity and liver diseasesConsistent with the critical role of YAP in liver physiology, dys-
egulation of YAP activity induces liver diseases in mouse models.
ore importantly, elevated YAP levels were constantly found inr Disease 47 (2015) 826–835
human liver diseases, especially liver cancer. In this section, we  will
summarize the studies revealed the links between YAP activity and
liver diseases.
3.1. YAP and liver cancer
Role of YAP in liver cancer demonstrated by animal models. The
ﬁrst evidence of YAP in driving liver cancer formation came from a
mouse model of liver cancer initiated from progenitor cells har-
bouring p53 loss and c-myc overexpression [40]. Genome wide
analysis of tumours in this mouse model revealed a recurrent
ampliﬁcation at mouse chromosome 9qA1 that contains Yap and
cIAP1 (cellular inhibitor of apoptosis protein-1). Interestingly, the
syntenic region of human chromosome 11q22 is ampliﬁed in a vari-
ety of human cancers [41–44]. Functional analysis indicated that
both cIAP1 and Yap contribute to tumorigenesis and are required to
sustain rapid growth of this amplicon-containing tumour.
The direct evidences of YAP in driving liver cancer came
from genetic modiﬁed mouse models with manipulations of
Hippo signalling pathway components (phenotypes summarized
in Tables 1 and 2). Transgenic overexpression of YAP in hepatocytes
(ApoE-rtTA; TRE Yap) leads to liver enlargement and hepatocellular
carcinoma (HCC) formation [9]. Similarly, increasing YAP activity by
liver-speciﬁc knockout of the Hippo signalling pathway upstream
tumour suppressors also leads to HCC and/or cholangiocarcinoma
(CC) formation. Two studies of Alb-Cre; Nf2f/f mice revealed liver-
speciﬁc deletion of Nf2 induces HCC and biliary tumour although
with some differences in mouse survival, time course of tumour
progression and the malignancy of biliary tumour, which is prob-
ably due to different mouse genetic background [15,27]. Germline
mutants of mammalian Hippo kinase orthologs Mst1 (Mst1−/−) or
Mst2 (Mst2−/−) are viable and fertile, without liver abnormality
[45], which may  be due to functional redundancy of MST1 and
MST2 as they share 76% identity in amino acid sequence [46].
However, liver speciﬁc deletion of Mst2 on Mst1 null background,
Alb-Cre; Mst1−/−;Mst2f/f and Ade-Cre;Mst1−/−;Mst2f/f, develop HCC
at 3 months of age or 10 weeks after Ade-Cre administration, respec-
tively [47]. It was  also reported that CAGGCre-ER; Mst1−/−;Mst2f/−
mice develop both HCC and CC by 6 months of age after postnatal
Tamoxifen administration [48]. Similarly but less aggressively, liver
speciﬁc knockout of Sav1 also resulted in mixed types of tumours
around one year of age [49,50]. More importantly, heterozygous
deletion of Yap, which results in no phenotypical manifestation by
itself, signiﬁcantly suppressed tumour formation in Alb-Cre; Nf2f/f
or Alb-Cre;Mst1−/−;Mst2f/f mice [15,34] (Table 2). These ﬁndings
provided strong evidences that YAP is the driver of tumour for-
mation in Nf2 or Mst1/2-deﬁcient livers.
Further evidences of YAP’s involvement in liver cancer came
from the hydrodynamic injection model and the carcinogen
induced mouse and rat HCC models. YAP and -catenin shows
concurrent nuclear localization in human hepatoblastoma (HB)
specimens and interacts with each other in HB cell line. Combined
hydrodynamic delivery of constitutively active Yap (YapS127A) and
constitutively active -catenin (N90/-catenin) to mouse liver
leads to HCC formation as early as 3 weeks after injection [51].
Increased YAP protein levels were found in HCCs developed in mice
given diethylnitrosamine (DENA) followed by repeated treatments
with 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) [52].
Nuclear YAP accumulation was observed in preneoplastic hepa-
tocytes generated in rats 4 weeks after DENA treatment, which
suggested YAP activation is an early event in liver tumorigenesis
[53]. Taken together, all these studies provided solid evidences that
Yap is a proto-oncogene in the context of liver.
Role of YAP in liver cancer demonstrated by human studies. In
humans, elevated YAP activity in different types of primary liver
cancers was observed by many studies (summarized in Table 3).
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Table  1
Liver phenotypes of genetically modiﬁed mice with manipulations of single Hippo pathway components.
Gene Genotype Phenotype Reference
Amot1 Alb-Cre;Amotf/f Normal [111]
Alb-Cre;Amotf/f + DDC13 Reduced levels of ductular reactions [111]
Fat2 Fat4−/− Death at birth [98]
Alb-Cre;Fat4f/f Normal [99]
RASSF3 Rassf1a−/− Increased tumour susceptibility [100,101]
Rassf5a−/− Normal [102]
Nf24 Nf2−/− Embryonically lethal between E6.5 and E7.0 [103]
Nf2+/− Develop a variety of tumours, 9% HCC16 [104]
AAV-Cre; Nf2f/f Hepatocyte dedifferentiation [24]
Alb-Cre;Nf2f/f Over-developed bile ducts, hepatomegaly, bile duct harmatoma or CC17, HCC [15,27]
Ade-Cre;Nf2f/f Mild periportal hyperplasia [27]
Ade-Cre;Nf2f/f + PH14 HCC and CC [27]
Mx1-Cre;Nf2f/f Mild OC18 proliferation [27]
Mx1-Cre;Nf2f/f +PH HCC and CC [27]
Mst1/25 Mst1−/− or Mst2−/− Normal [45,47,48,50]
Mst1−/−;Mst2+/− Hepatomegaly, HCC by 7 months [47,48]
Mst1+/−;Mst2−/− Low incidence HCC by 15 months [47,48]
Mst1−/−;Mst2−/− Embryonically lethal at E8.5 [47,48,50,105]
Alb-Cre; Mst1/2f/f Hepatomegaly, HCC at 5–6 months [48,50]
Alb-Cre; Mst1−/−;Mst2f/f Hepatomegaly, HCC by 3 months [47]
Alb-Cre; Mst1−/−;Mst2f/− Hepatomegaly, HCC at 1 month [48]
Ade-Cre; Mst1−/−;Mst2f/f or Ade-Cre; Mst1−/−;Mst2f/− Hepatomegaly, lethal HCC 10 weeks after Ade-Cre injection [47]
CAGGCre-ER; Mst1−/−;Mst2f/− Hepatomegaly, HCC and CC at 6 months [48]
Sav16 Sav1−/− Embryonically lethal around E17.5 to E18.5 [106]
Sav1+/− 74% mice developed liver tumours [49]
Alb-Cre; Sav1f/f Hepatomegaly, HCC and CC by 13–14 months [49,50]
MMTV-Cre; Sav1f/f Liver tumours by 14 months [50]
Caggs-creER(T2); Sav1f/f Liver tumours by 14 months [50]
Lats1/27 Lats1−/− Neonatal death, infertility and growth retardation [107]
Lats2−/− Embryonically lethal on or before E12.5 [108]
Mob18 Mob1a−/− or Mob1btr/tr Normal [109]
Mob1a−/−;Mob1btr/tr Embryonically lethal [109]
Mob1a−/−;Mob1btr/+ 50% liver tumours [109]
Yap9 ApoE-rtTA; TRE Yap Hepatomegaly, HCC [9]
LAP1-tTA;TetO-YapS127A Hepatomegaly [97]
Ck19-CreERT;TetO-Yap S127A Ductal hyperplasia [24]
AAV-Cre; TetO-YapS127A Hepatomegaly, Hepatocyte dedifferentiation [24]
Yap−/− Embryonically lethal at E8.5 [14]
Alb-Cre;Yapf/f Bile duct paucity [15]
Mx1-Cre;Yapf/f Normal [26]
Mx1-Cre;Yapf/f + BDL15 More severe liver injury [26]
Taz10 Taz−/− Minor skeletal defects, renal cysts [110]
TEAD11 Alb-rtTA;TRE TEAD2-DN Normal [11]
Vgl412 ApoE-rtTA; TRE Vgl4 Normal [12]
1Amot, angiomotin; 2Fat, FAT atypical cadherin; 3RASSF, Ras Association (RalGDS/AF-6) Domain Family; 4Nf2, neuroﬁbromin 2; 5Mst1/2, Mammalian STE20-Like Protein
K  1/2;
1 rbony
h
C
h
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T
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1
Minase  1/2; 6Sav1, salvador homolog 1; 7Lats1/2; large tumour suppressor homolog
1TEAD, TEA domain family members; 12Vgl4, Vestigial like 4; 13DDC, 3,5-diethoxyca
epatocellular carcinoma; 17CC, cholangiocarcinoma; 18OC, oval cell.
onsistently, most research groups observed more than 50% of
uman liver cancer tumours show elevated nuclear YAP expression
9,51,54–60]. Multiple mechanisms were attributed to the ele-
ated nuclear YAP expression, including gene ampliﬁcation [40,56],
ncreased Yap mRNA levels [51,55,56] and the dysregulation of the
able 2
iver phenotypes of genetically modiﬁed mice with manipulations of combined Hippo pa
Gene Genotype 
Nf21&Amot2 Alb-Cre;Nf2f/f;Amotf/f
Nf2&Fat43 Alb-Cre;Nf2f/f; Fat4f/f
Nf2&Yap4 Alb-Cre;Nf2f/f; Yapf/f
Alb-Cre;Nf2f/f; Yapf/+
Nf2&TEAD5 Alb-Cre;Nf2f/f;Alb-rtTA;TRE TEAD2-DN 
Nf2&Vgl46 Alb-Cre;Nf2f/f;ROSA26-loxP-STOP-loxP-rtTA;TREVgl4 
Mst1/27&Yap Alb-Cre; Mst1−/−;Mst2f/f;Yapf/+
Alb-Cre; Mst1−/−;Mst2f/f;Yapf/f
Yap&TEAD ApoE-rtTA;TRE Yap; TRE TEAD2-DN
Yap&Vgl4 ApoE-rtTA;TRE Yap; TRE Vgl4 
Yap&Rbpj8 AAV-Cre;TetO YapS127A; Rpbjf/f
Nf2, neuroﬁbromin 2; 2Amot, angiomotin; 3Fat4, FAT atypical cadherin 4; 4Yap, Yes-assoc
ammalian STE20-Like Protein Kinase 1/2; 8Rbpj, recombination signal binding protein f8Mob1, Mps  One Binder Homolog A; 9Yap, Yes-associated protein; 10Taz, tafazzin;
l-1,4-dihydrocollidine; 14PH, partial hepatectomy; 15BDL, bile duct ligation; 16HCC,
Hippo signalling with reduced expression of MST1 [47], LATS [57]
and RASSF1A [59]. Several genes were proposed as YAP down-
stream targets in driving liver cancer development, including Axl
(AXL receptor tyrosine kinase)  [61], Survivin [56] and Amphiregulin
[59]. Combining human and mouse data together, YAP is a very
thway components.
Phenotype Reference
Suppressed Nf2 phenotype [111]
Nf2 phenotype is not suppressed [99]
Suppressed Nf2 phenotype [15]
Suppressed Nf2 phenotype [15]
Suppressed Nf2 phenotype [11]
Completely suppressed Nf2 phenotype [12]
Suppressed Mst1/2 phenotype [34]
Suppressed Mst1/2 phenotype
Suppressed YAP overexpression phenotype [11]
Suppressed YAP overexpression phenotype [12]
Suppressed YAP overexpression phenotype [24]
iated protein; 5TEAD, TEA domain family members; 6Vgl4, Vestigial like 4; 7Mst1/2,
or immunoglobulin kappa J region.
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Table 3
Summary of Yes-associated protein expression survey studies in human liver cancer samples.
Cancer type Patients origin No. control
samples
Nuclear YAP8
expression
No. tumour
samples
Nuclear YAP
expression
Paired con-
trol/tumour?
Reference
HCC1 USA6 N/A7 N/A 20 65% N9 [9]
HCC USA 42 5% 115 54% N [54]
HCC Hong Kong 177 9.0% 177 62.1% Y10 [55]
HCC USA 38 25% 70 85% N [57]
HCC USA 83 28% 87 71% Y [56]
HCC China 20 5% 40 42.5% N [58]
HCC China 10 Very low 70 51.4% N [60]
HCC Korea 15 20% 22 73% N [59]
HCC Korea N/A N/A 100 31% N [59]
HCC Europe N/A N/A 103 65% N [51]
CC2 USA 8 N/A 16 98% N [57]
ICC3 USA 5 None 10 90% N [56]
ICC Europe N/A N/A 62 98% N [51]
cHCC-CC4 Korea N/A N/A 58 67.2% N [59]
HB5 USA 5 N/A 22 73% Y [57]
HB Europe/USA N/A N/A 94 85% N [51]
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hHCC, hepatocellular carcinoma; 2CC, cholangiocarcinoma; 3ICC, intrahepatic chol
lastoma; 6USA, United States of America; 7N/A, not available; 8YAP, Yes-associated
romising therapeutic target for liver cancer. Further studies need
o focus on how to efﬁciently and speciﬁcally inhibit YAP activity.
.2. YAP and other liver diseases
Besides liver cancer, dysregulation of YAP activity was con-
tantly observed in biliary diseases, which is in consistence with
he role of YAP in bile duct homeostasis. Elevated nuclear YAP
xpression was found in ductular reactions of primary sclerosing
holangitis (PSC) and primary biliary cirrhosis (PBC) [26] as well
s in bile duct epithelium of neonates with biliary atresia [62]. In
holestatic livers of young patients, hepatocytes also display robust
AP staining [63]. Whether YAP plays a role in other liver diseases
s an interesting question and remains to be investigated.
. Regulatory mechanisms of YAP activity in the liver
In the previous sections, we summarized accumulative evi-
ences showing that precise regulation of YAP activity is critical
or liver homeostasis and tumorigenesis. Therefore, it is impor-
ant to completely understand the mechanisms that regulate
AP activity. Multiple mechanisms including mRNA transcription,
ost-transcriptional modiﬁcation, nucleocytoplasmic transporta-
ion and protein stability participate in regulating YAP activity. In
his section, we  will review up-to-date discoveries on these regu-
atory mechanisms in the liver (Fig. 2).
.1. Yap mRNA transcription
Several transcription factors including GABP (GA-binding pro-
ein), homeobox protein NANOG and CREB (cAMP response
lement-binding protein) were reported to occupy Yap promoter
egion and upregulate Yap mRNA transcription in mouse liver or
CC cells. Wu  et al. used Yap promoter region as bait to pull down
he binding proteins from mouse liver lysate and identiﬁed Ets
amily transcription factor complex GABP/GABP as candidate
31]. Yap promoter contains 16 Ets family transcription factor bind-
ng site (EBS) and multiple EBS sequences were bound by GABP
o regulate Yap transcription. Interestingly, GABP is phosphory-
ated and inhibited by LATS1, which indicates that Hippo signalling
egulates YAP activity through both phosphorylation and tran-
cription [31]. Functional screening for oncogenes regulated by
LR4 (Toll-like receptor 4) and NANOG using a lentiviral cDNA
ibrary from tumour-initiating stem-like cells (TICs) in mouse and
uman HCC tumours revealed YAP as one of the candidates [64].carcinoma; 4HCC-CC, combined hepatocellular-cholangiocarcinoma; 5HB, hepato-
ein; 9N, no; 10Y, yes.
Chip-qPCR assay indicated that NANOG binds to two NANOG con-
sensus sites in Yap promoter (−1294 and −323 nt). Two studies
using HCC cell lines suggested CREB regulates Yap mRNA transcrip-
tion but mapped CREB binding sites to different regions of Yap
promoter [58,65]. Zhang et al. mapped the CREB binding region
on Yap promoter to be −232/+115, where is also occupied by HBx
(Hepatitis B virus X protein) to activate Yap transcription through
CREB [58]. Wang et al. mapped the CREB binding region on Yap
promoter to be −608/−439 [65]. Amphiregulin and HB-EGF (epi-
dermal growth factor) treatment is able to increase Yap mRNA
levels through EGFR (epidermal growth factor receptor) and MEK1
(Dual speciﬁcity mitogen-activated protein kinase kinase 1), but it
is not clear how EGFR signalling increases Yap transcription [66].
Yap transcription is regulated epigenetically by Menin. As a scaf-
fold protein, Menin partners with mixed-lineage leukemia (MLL)
histone methyltransferase to regulate the transcription of target
genes by altering histone tail modiﬁcations [67]. In an effort to
identify the promoters occupied by Menin, Xu et al. performed
ChIP-on-chip screens with Menin antibody in HepG2 cells [68].
Yap is one of the top picks with promoter occupied by Menin
coinciding with the transcriptional activation of H3 modiﬁcation.
Interestingly, Menin epigenetically upregulates Yap transcription
speciﬁcally in HCC cell lines as although Menin binds to the pro-
moter of Yap in other types of cell lines including MCR-7, Wilm’s
and A549, there are no obvious effects on H3K4me3 levels at Yap1
foci by Menin overexpression.
4.2. Post transcriptional modiﬁcation to Yap mRNA
Liu et al. used bioinformatics technology to screen miRNAs that
may  target the 3′ UTR region of Yap gene for degradation and
identiﬁed miR-375 as a candidate [69]. Luciferase reporter assay
conﬁrmed that miR-375 indeed targets the 3′ UTR region of Yap
gene. Ectopic expression of miR-375 decreased endogenous YAP
protein levels as well as YAP transcriptional target – Ctgf (connec-
tive tissue growth factor)  mRNA levels in PLC and 97L HCC cell lines.
Consistently, elevated YAP activity correlate with down-regulation
of miR-375 in human HCC tissues, chemical-induced mouse HCC
model and DENA-induced rat preneoplastic hepatocytes [52,53,69].
4.3. YAP protein phosphorylation/nucleocytoplasmic shuttlingYAP phosphorylation mediated by the Hippo signalling rep-
resents the major regulation strategy of YAP activity. As a
transcription coactivator, nuclear accumulation is necessary for
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Fig. 2. Mediators of Yes-associated protein activity in the liver. In the liver, Yes-associated protein activity is regulated through multiple mechanisms including transcription,
post  transcriptional modiﬁcation, phosphorylation and protein degradation. Transcriptional factors GA-binding protein, homeobox protein NANOG, cAMP response element-
binding protein/Hepatitis B virus X protein and scaffold protein Menin bind to Yes-associated protein promoter region to promote Yes-associated protein mRNA transcription.
miR375 interacts with 3′ UTR of Yes-associated protein mRNA to promote mRNA degradation and inhibit translation. Association between Yes-associated protein and its
transcription factor partner TEA domain family members can be inhibited by competitively binding of Vestigial like protein 4 or through phosphorylation by the Hippo
pathway. Yes-associated protein Phosphorylation by the Hippo signalling pathway primes its further phosphorylation by casein kinase 1/, which leads to Yes-associated
protein  degradation through proteasome. Yes-associated protein degradation can be inhibited by TEA domain family members interaction. Bile acids inhibit Yes-associated
protein  phosphorylation through IQ Motif Containing GTPase Activating Protein 1. Active Hippo signalling pathway can also leads to GA-binding protein  phosphorylation,
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AP’s function. Nuclear accumulation or cytoplasmic retention
epends on YAP’s phosphorylation status. Dephosphorylated YAP
ccumulates in nucleus while phosphorylation at Ser127 (human,
er112 in mouse YAP) by LATS1/2 kinase due to activated Hippo
ignalling sequesters YAP in the cytoplasm via 14-3-3 interac-
ion [9]. In mouse liver, ablation of the Hippo signalling pathway
pstream tumour suppressors Nf2, Mst1/2 or Sav1 all resulted in
educed levels of phosphorylated YAP, which in turn drives liver
umorigenesis [15,47,49]. Using HCC cell lines, overexpression of
nother Hippo signalling pathway upstream tumour suppressor
ASSF1A (Ras Association (RalGDS/AF-6) Domain Family Member
) increased YAP phosphorylation [59].
Other than the Hippo pathway, bile acid regulates YAP phos-
horylation through IQGAP1 (IQ motif containing GTPase activating
rotein 1) in the liver [63]. Phosphor-YAP levels were downreg-
lated in the presence of elevated bile acid levels in Fxr−/−Shp−/−
ice or WT  mice fed with 1% cholic acid. IQGAP1 is required for bile
cid-induced YAP activation as 1% cholic acid diet failed to induce
AP activation in Iqgap1−/− mice. Furthermore, adenoviral Iqgap1
verexpression in WT  liver was sufﬁcient to increase YAP protein
evels. As a key scaffolding protein that interacts with E-cadherin,
QGAP1 overexpression reduces cellular adhesion by dissociating
-catenin from the cadherin–catenin complex [70]. These results
ndicated that elevated bile acid levels reduce hepatic cell adhesion
hrough disrupting E-cadherin junctions, which in turn activates
AP. E-cadherin junction disruption has been previously reported
s an evoking event of YAP activation in breast cancer cell lines [71].
In Drosophila or non-hepatic mammalian cells, multiple
pstream inputs including extracellular matrix area and stiffness GABP, GA-binding protein; CREB, cAMP response element-binding protein; HBx,
1/, casein kinase 1/; IQGAP1, IQ Motif Containing GTPase Activating Protein 1.
[72,73], cell density [54], cell detachment [74], F-actin cytoskele-
ton [75], spectrin cytoskeleton [76,77], and cellular energy level
[78,79] were shown to regulate YAP nuclear accumulation depend-
ent or independent of the canonical Hippo signalling. Detailed
reviews of these upstream YAP regulators can be found elsewhere
[80,81]. Serum-derived small molecules sphingosine-1-phosphate
(S1P) and lysophosphatidic acid (LPA) are particularly interesting
because they are the ﬁrst extracellular diffusible factors regulating
YAP activity [82,83]. S1P and LPA act through GPCRs (G-protein-
coupled receptors) G12/13 to inhibit the Hippo pathway kinase
LATS1/2, which in turn activates YAP [83]. Whether these upstream
inputs regulate YAP activity in the context of liver requires further
investigation.
4.4. YAP protein stability
Another strategy that cell employs to regulate YAP protein levels
is protein stability [11,84]. Overexpression of YAP’s transcriptional
partner, TEAD, signiﬁcantly increased YAP protein levels but not
Yap mRNA levels in mouse liver and as well as in HEK293 cells,
suggesting TEAD binds and stabilizes YAP, which is further sup-
ported by the observation that YAP S94A (human, Ser79 in mouse
YAP), a mutant form defective in TEAD binding, had a shorter
half-life than wild-type YAP [11]. Binding to TEAD may  keep YAP
in active form thus inhibit YAP protein degradation initiated by
LATS1/2 phosphorylation. LATS1/2 can phosphorylate YAP at all the
ﬁve consensus HxRxxS motifs. Among these phosphorylatable ser-
ine/threonine residues, phosphorylation at S381 (human, Ser363
in mouse YAP) primes this region for further phosphorylation by
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K1/ (casein kinase 1/) at Ser384 (human, Ser366 in mouse
AP) and S387 (human, Ser369 in mouse YAP) to generate a phos-
horylated phosphodegron that will recruit SCF-TRCP E3 ubiquitin
igase. Ubiquitination by SCF-TRCP E3 ubiquitin ligase then leads
AP to proteasome degradation [84].
Although multiple mechanisms have already been revealed,
urther efforts are still needed for a complete understanding of
AP activity regulation. For example, YAP protein levels elevate
n mouse livers following BDL [26]. However, the phosphorylation
tatus of YAP and Yap mRNA levels remain stable excluding involve-
ent of Hippo signalling and transcriptional regulation, which
uggested other mechanisms of YAP activity regulation. Moreover,
t will be also important to deﬁne the contributions of various
egulating mechanisms to YAP activity in different physiological
ontexts.
. YAP transcriptional partners and targets in the liver
As a transcription coactivator, YAP does not bind to DNA directly
ut, rather, partners with DNA-binding transcription factors. Stud-
es in mammalian cells have revealed several transcription factor
artners for YAP including the p53 family p73 [85], the Runt family
ember Runx2 [86], and the TEAD/TEF family transcription factors
10]. Among these reported YAP-interacting partners, TEAD/TEF
amily transcription factors are identiﬁed as the major mediators
f YAP function in mammalian cells [87,88]. To investigate whether
AP functions through TEAD factors in intact mammalian tissues,
EAD proteins were inactivated speciﬁcally and conditionally in the
ouse liver [11]. The mouse genome contains four highly homol-
gous TEAD family members, all of which are expressed in the
iver. Because different TEAD members appear to function redun-
antly [89], dominant-negative scheme was employed to block
he activity of all four TEAD factors with engineering a truncated
orm of TEAD2 that lacks its DNA-binding domain (TEAD2-DN) [11].
o-overexpression of YAP and TEAD2-DN in mouse hepatocytes
otently suppressed hepatomegaly and tumorigenesis caused by
AP overexpression or loss of NF2. Thus, TEAD is the major partner
f YAP in the liver to induce the transcription of YAP’s downstream
argets.
mRNA microarray analysis has revealed a large number of genes
hat are induced by YAP in mouse livers [9,24,50]. Among these
andidate YAP target genes, Axl is a direct target of YAP and has
een shown to contribute to YAP-dependent oncogenic functions
n HCC cell lines [61]; Ctgf [54] and Amphiregulin [90] were shown
o be direct targets of YAP using non-liver cell lines and found to
e induced by YAP in mouse liver [91] and HCC cell lines [59],
espectively; in human liver cancer survey studies, expression lev-
ls of CTGF, Survivin and Glypican 3 were found to correlate with
AP activity levels [56,57]. Two independent studies have put YAP
pstream of the Notch signalling pathway [23,24]. YAP activation
n mouse livers increases mRNA levels of several Notch pathway
omponents including Notch1/2, Jag1 (Jagged 1), Hes1 (hes family
HLH transcription factor 1) and Sox9 (sex determining region Y-box
) [23,24], among which Notch2 is a direct target of YAP [24]. More
mportantly, Notch inhibition through Rbpj (recombination signal
inding protein for immunoglobulin kappa J region)  deletion damp-
ns the hepatocyte-to-ductal dedifferentiation phenotype in Yap
ransgenic liver, which put the Notch signalling downstream of YAP
ith genetic studies in intact mammalian tissue.
Other than inducing target gene expression transcriptionally,
AP also exerts its inﬂuence through protein-protein interactions.
AP interaction with SMAD7/SMAD3 in the cytoplasm results in
ytoplasmic retention of SMAD3, then in turn leads to inactivation
f the canonical TGF- signalling, which contributes to tumour-
nitiating stem-like cell formation in HCC caused by HCV and/orr Disease 47 (2015) 826–835
alcohol-related chronic liver injury [64]. In HCC cell lines, YAP pro-
motes CREB protein stability through interaction with MAPK14/p38
(mitogen-activated protein kinase 14) and BTRC (beta-transducin
repeat containing E3 ubiquitin protein ligase) [65]. c-Myc transcrip-
tion is indirectly regulated by YAP through interaction with c-Abl
[92].
6. YAP as therapeutic target in liver cancer
The current available data including YAP upregulation in human
liver cancer, the tumorigenic phenotypes of mouse liver-speciﬁc
Nf2/Mst/Sav knockouts and Yap transgenic overexpression, sug-
gests that increased YAP activity is a driving event for liver cancer
formation. The fast advance of our knowledge to YAP’s regulators
and regulations made it possible to inhibit YAP activity with mul-
tiple schemes.
6.1. Reducing YAP protein levels
Reducing YAP protein levels is the most direct strategy to
decrease YAP activity. Using Yap siRNA encapsulated into LNPs
(siYap-LNPs), which improves the cellular uptake, stability and
pharmacokinetics of the siRNA, Fitamant et al. demonstrated that
tail vein injection of siYap-LNPs dramatically reduced liver tumour
burden of Mst1/2-deﬁcient mice [34]. Importantly, the treatment
regimen was  well tolerated only inducing a slight inﬂammation in
periportal areas that was fully resolved within a short time follow-
ing discontinuation of treatment.
6.2. Disrupting YAP–TEAD interaction
Using genetic modiﬁed mouse models, Liu-Chittenden and
colleagues demonstrated that the tumorigenic potential of YAP
in mouse liver requires association to TEAD [11], which makes
YAP–TEAD interaction an ideal drug target. By screening the Johns
Hopkins Drug Library, they identiﬁed members of the porphyrin
family as small molecule inhibitors of YAP–TEAD interactions.
One of these inhibitors, verteporﬁn (VP) is used clinically as a
photosensitizer in photodynamic therapy for neovascular macu-
lar degeneration. Administration of VP to YAP transgenic mice and
Nf2 knockout mice signiﬁcant suppressed hepatomegaly caused by
hepatocyte and biliary cell proliferation, respectively, in these two
mouse models, without overt adverse effects in other organs [11].
Additionally, VP treatment reduced cell proliferation more pro-
nouncedly in HuCCT1 cholangiocarcinoma cell line than it did to
normal cholangiocyte cell line H69, suggesting the potential of VP
in treating cholangiocarcinoma [62].
Although YAP mainly functions through TEAD, it is not the only
transcription cofactor of TEAD. Vgl4 competes with YAP on bind-
ing to TEAD via TDU domains [12,93,94]. Animal studies indicated
that Vgl4 overexpression signiﬁcantly suppressed transgenic YAP-
induced liver overgrowth and tumorigenesis [12], which suggested
a potential therapeutic application of Vgl4 in cancer therapy. Jiao
and colleagues resolved the crystal structure of mouse Vgl4 tan-
dem TDU region in complex with the YBD domain of mouse TEAD4,
and based on this complex structure, they designed a “Super-TDU”
peptide to inhibit YAP–TEAD interaction [94]. Administration of
Super-TDU peptide to Helicobacter pylori and N-methyl-N′-nitro-
N-nitrosoguanidine (MNNG) induced-gastric cancer mouse models
signiﬁcantly suppressed tumour numbers and tumour cell prolif-
eration.6.3. Targeting YAP upstream regulators
The Hippo signalling pathway. The Hippo signalling path-
way is the major upstream negative regulator of YAP activity.
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levated Hippo signalling activities will efﬁciently inhibit YAP
ctivity. Integrin-linked kinase (ILK) suppresses the Hippo
ignalling pathway via phospho-inhibition of MYPT1-PP1 (myosin
hosphatase target subunit 1-protein phosphatase 1), leading to
nactivation of NF2 [95]. Pharmaceutical inhibition of ILK with
LT0267 in tumour cell lines and mouse xenograft models suppress
AP-dependent tumour growth. However, this approach requires
n intact Hippo pathway signal ﬂow in tumour cells.
F-actin cytoskeleton. F-actin cytoskeleton is fundamental to sus-
ain YAP function. A mild disruption of the actin cytoskeleton leads
o dramatic inhibition of YAP nuclear localization [72,74,96]. There-
ore, factors those contribute to the actin cytoskeleton integrity
ay  have therapeutic potential in inhibiting YAP activity. Indeed,
he ROCK inhibitor Y27632 and the nonmuscle myosin heavy chain
nhibitor blebbistatin have been shown to inhibit YAP activity
72,96]. The potential of these inhibitors in treating YAP-dependent
umours needs to be further evaluated in animal models.
AMP-activated kinase (AMPK). Cellular energy stress nega-
ively regulates YAP activity through AMPK, which is a critical
nergy level sensor and mediator [78,79]. Pharmacological activa-
ion of AMPK by AMPK activators, aminoimidazole carboxamide
ibonucleotide (AICAR) or metformin, signiﬁcant suppressed
nchorage-independent growth of Lats-null cells with high YAP
ctivity. Furthermore, metformin inhibited tumour growth of Lats-
ull cells xenografted mice [79].
.4. Targeting YAP downstream events
Downstream targets that are essential in YAP-driven tumori-
enesis also have therapeutic potentials. For example, the Notch
ignalling has been indicated to be important downstream of
AP for the development of YAP-driven liver hyperplasia [24].
herefore, YAP-driven tumours might beneﬁt from treatment with
otch inhibitors. Indeed, administration of -secretase inhibitor
uppressed transgenic YAP induced dysplastic phenotype in the
ntestine [97].
. Concluding remarks
Beneﬁted from serving as the model organ for the Hippo
ignalling research in the past several years, our understanding of
he physiological function and molecular mechanism of YAP in the
ouse liver has been greatly advanced. These studies have ﬁrmly
stablished YAP as a critical regulator of liver development and
omeostasis. The importance of YAP in the liver is further solidi-
ed by the realization that elevated YAP activity drives liver cancer
evelopment, which makes small molecules inhibiting YAP activ-
ty have very promising therapeutic potentials for this devastating
isease.
Despite recent progress, our knowledge about this important
ncogene remains incomplete. First of all, comparing to the rapid
dditions of YAP’s upstream regulators, the outputs of YAP remain
ncompletely deﬁned, especially in intact mammalian tissues. A
ajor challenge in the future is to elucidate the molecular nature
f these outputs, and the molecular mechanisms that contribute to
AP’s physiological function. Another challenge is to fully under-
tand the molecular mechanisms that regulate YAP protein level.
reviously most attention was paid to YAP activation by dephos-
horylation. However, clinical survey indicated elevated total YAP
rotein levels are commonly observed in human tumour samples.
n combination with the realization that mutations in the Hippo
ignalling pathway are rarely observed in human cancer, dysreg-
lation of YAP protein levels may  be a more commonly employed
cheme by cancer cells.r Disease 47 (2015) 826–835 833
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